COL‑3 enhances the anti‑proliferative and pro‑apoptotic effects of paclitaxel in breast cancer cells

El‑Tabba',Roba   M.; Mathew,Princy; Masocha,Willias; Khajah,Maitham   A.

doi:10.3892/or.2018.6815

COL‑3 enhances the anti‑proliferative and pro‑apoptotic effects of paclitaxel in breast cancer cells

Authors:
- Roba M. El‑Tabba'
- Princy Mathew
- Willias Masocha
- Maitham A. Khajah
View Affiliations

Affiliations: Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, PO Box 24923, Safat 13110, Kuwait
Published online on: October 22, 2018 https://doi.org/10.3892/or.2018.6815
Pages: 630-642

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Paclitaxel, a chemotherapeutic agent used in the treatment of breast cancer and other solid tumor types, including ovarian and lung, causes a dose‑dependent neuropathic pain, which limits its use. Chemically modified tetracycline‑3 (COL‑3) has anticancer properties and was previously reported to inhibit neuroinflammation and protect against paclitaxel‑induced neuropathic pain (PINP) in mice models. However, it is not known whether it affects the anticancer activities of paclitaxel. Thus, the aim of the present study was to evaluate the effect of COL‑3 on the anticancer activity of paclitaxel on the breast cancer cell lines MCF‑7 (estrogen receptor‑positive), pII [estrogen receptor‑negative (ER‑ve)] and MDA‑MB‑231 (ER‑ve). Cell proliferation, apoptosis and cell cycle stage were determined using an MTT assay, Annexin V/7‑aminoactinomycin D and flow cytometry. The expression of various signaling molecules was determined with ELISA‑based proteome profiling and western blotting. Additionally, the degree of cell invasion was determined with a Matrigel assay and caspase‑3 activity was determined with a colorimetric assay. Treatment with paclitaxel or COL‑3 alone inhibited cell proliferation in a concentration‑dependent manner in all cell lines. The anti‑proliferative effects of paclitaxel and COL‑3 in combination varied from synergism against MDA‑MB‑231 and pII cells to notably additive and slight antagonism against MCF‑7 cells. In the highly proliferative and invasive pII cells, the observed synergistic anti‑proliferative effect was partially through the induction of apoptosis via modulation of caspase‑3 levels and activity, and P70S6K phosphorylation, but not cell cycle arrest. COL‑3 inhibited the invasion of pII cells in a concentration‑dependent manner partially through inhibiting total matrix metalloproteinase activity. The combination regimen significantly inhibited the expression of two proteases, ADAM metallopeptidase with thrombospondin type 1 motif 1 and proteinase 3. In conclusion, the combination of paclitaxel and COL‑3 indicated additive to synergistic anti‑proliferative effects on breast cancer cells mediated partially via the induction of apoptosis. The combination regimen could further inhibit invasion and metastasis. Thus, COL‑3 could be a beneficial adjunct to a paclitaxel‑based anticancer regimen to improve therapeutic outcome and reduce the adverse effects of paclitaxel, primarily PINP.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 12:214922018.
2	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hernandez-Aya LF and Gonzalez-Angulo AM: Adjuvant systemic therapies in breast cancer. Surg Clin North Am. 93:473–491. 2013. View Article : Google Scholar : PubMed/NCBI
4	Clark GM, Osborne CK and McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 2:1102–1109. 1984. View Article : Google Scholar : PubMed/NCBI
5	Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV and Foekens JA: Tamoxifen resistance in breast cancer: Elucidating mechanisms. Drugs. 61:1721–1733. 2001. View Article : Google Scholar : PubMed/NCBI
6	Hassan MS, Ansari J, Spooner D and Hussain SA: Chemotherapy for breast cancer (Review). Oncol Rep. 24:1121–1131. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mincey BA, Palmieri FM and Perez EA: Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials. Oncologist. 7:246–250. 2002. View Article : Google Scholar : PubMed/NCBI
8	Rowinsky EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 48:353–374. 1997. View Article : Google Scholar : PubMed/NCBI
9	Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA. 77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
10	Woods CM, Zhu J, McQueney PA, Bollag D and Lazarides E: Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med. 1:506–526. 1995. View Article : Google Scholar : PubMed/NCBI
11	Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H and Wilson L: Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res. 56:816–825. 1996.PubMed/NCBI
12	Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
13	Crown J and O'Leary M: The taxanes: An update. Lancet. 355:1176–1178. 2000. View Article : Google Scholar : PubMed/NCBI
14	Esin E and Yalcin S: Neuropathic cancer pain: What we are dealing with? How to manage it? Onco Targets Ther. 7:599–618. 2014.PubMed/NCBI
15	Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, et al: ; American Society of Clinical Oncology: Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 32:1941–1967. 2014. View Article : Google Scholar : PubMed/NCBI
16	Parvathy SS and Masocha W: Matrix metalloproteinase inhibitor COL-3 prevents the development of paclitaxel-induced hyperalgesia in mice. Medical principles and practice: International journal of the Kuwait University. Health Sci Cent. 22:35–41. 2013.
17	Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA and Rifkin BR: Tetracyclines inhibit connective tissue breakdown: new therapeutic Implications for an old family of drugs. Crit Rev Oral Biol Med. 2:297–321. 1991. View Article : Google Scholar : PubMed/NCBI
18	Golub LM, Suomalainen K and Sorsa T: Host modulation with tetracyclines and their chemically modified analogues. Curr Opin Dent. 2:80–90. 1992.PubMed/NCBI
19	Gu Y, Lee HM, Simon SR and Golub LM: Chemically modified tetracycline-3 (CMT-3): A novel inhibitor of the serine proteinase, elastase. Pharmacol Res. 64:595–601. 2011. View Article : Google Scholar : PubMed/NCBI
20	Lokeshwar BL: Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol Res. 63:146–150. 2011. View Article : Google Scholar : PubMed/NCBI
21	Al Saleh S, Al Mulla F and Luqmani YA: Estrogen receptor silencing induces epithelial to mesenchymal transition in human breast cancer cells. PLoS One. 6:e206102011. View Article : Google Scholar : PubMed/NCBI
22	Luqmani YA, Al Azmi A, Al Bader M, Abraham G and El Zawahri M: Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells. Int J Oncol. 34:231–242. 2009.PubMed/NCBI
23	Khajah MA, Al Saleh S, Mathew PM and Luqmani YA: Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells. PLoS One. 7:e418472012. View Article : Google Scholar : PubMed/NCBI
24	Khajah MA, Mathew PM and Luqmani YA: Inhibitors of PI3K/ERK1/2/p38 MAPK show preferential activity against endocrine-resistant breast cancer cells. Oncol Res. 25:1283–1295. 2017. View Article : Google Scholar : PubMed/NCBI
25	Khajah MA, Mathew PM, Alam-Eldin NS and Luqmani YA: Bleb formation is induced by alkaline but not acidic pH in estrogen receptor silenced breast cancer cells. Int J Oncol. 46:1685–1698. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chou TC: Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 58:621–681. 2006. View Article : Google Scholar : PubMed/NCBI
27	Chou TC, Tan QH and Sirotnak FM: Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol. 31:259–264. 1993. View Article : Google Scholar : PubMed/NCBI
28	Al Saleh S, Sharaf LH and Luqmani YA: Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
29	Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, et al: Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer. 6:29–40. 1999. View Article : Google Scholar : PubMed/NCBI
30	Lee JJ and Swain SM: Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 24:1633–1642. 2006. View Article : Google Scholar : PubMed/NCBI
31	Chen Y, Yang C and Wang ZJ: Proteinase-activated receptor 2 sensitizes transient receptor potential vanilloid 1, transient receptor potential vanilloid 4, and transient receptor potential ankyrin 1 in paclitaxel-induced neuropathic pain. Neuroscience. 193:440–451. 2011. View Article : Google Scholar : PubMed/NCBI
32	Nishida K, Kuchiiwa S, Oiso S, Futagawa T, Masuda S, Takeda Y and Yamada K: Up-regulation of matrix metalloproteinase-3 in the dorsal root ganglion of rats with paclitaxel-induced neuropathy. Cancer Sci. 99:1618–1625. 2008. View Article : Google Scholar : PubMed/NCBI
33	D'Agostino P, Ferlazzo V, Milano S, La Rosa M, Di Bella G, Caruso R, Barbera C, Grimaudo S, Tolomeo M, Feo S, et al: Chemically modified tetracyclines induce cytotoxic effects against J774 tumour cell line by activating the apoptotic pathway. Int Immunopharmacol. 3:63–73. 2003. View Article : Google Scholar : PubMed/NCBI
34	Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer. 68:1104–1109. 1993. View Article : Google Scholar : PubMed/NCBI
35	Liu K, Cang S, Ma Y and Chiao JW: Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int. 13:102013. View Article : Google Scholar : PubMed/NCBI
36	Tommasi S, Mangia A, Lacalamita R, Bellizzi A, Fedele V, Chiriatti A, Thomssen C, Kendzierski N, Latorre A, Lorusso V, et al: Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of beta-tubulins. Int J Cancer. 120:2078–2085. 2007. View Article : Google Scholar : PubMed/NCBI
37	Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME and Weaver BA: Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 6:229ra432014. View Article : Google Scholar : PubMed/NCBI
38	Izbicka E, Campos D, Carrizales G and Patnaik A: Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res. 25:3215–3223. 2005.PubMed/NCBI
39	Tokuda E, Seino Y, Arakawa A, Saito M, Kasumi F, Hayashi S and Yamaguchi Y: Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 133:427–436. 2012. View Article : Google Scholar : PubMed/NCBI
40	Gu Y, Lee HM, Roemer EJ, Musacchia L, Golub LM and Simon SR: Inhibition of tumor cell invasiveness by chemically modified tetracyclines. Curr Med Chem. 8:261–270. 2001. View Article : Google Scholar : PubMed/NCBI
41	Lokeshwar BL, Escatel E and Zhu B: Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3). Curr Med Chem. 8:271–279. 2001. View Article : Google Scholar : PubMed/NCBI
42	Lokeshwar BL, Selzer MG, Zhu BQ, Block NL and Golub LM: Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 98:297–309. 2002. View Article : Google Scholar : PubMed/NCBI
43	Meng Q, Xu J, Goldberg ID, Rosen EM, Greenwald RA and Fan S: Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells. Clin Exp. 18:139–146. 2000. View Article : Google Scholar
44	Zhao L, Xu J, Yang Y, Chong Y, Liu C, Jiao Y and Fan S: Inhibitory impacts of chemically modified tetracycline-3 and underlying mechanism in human cervical cancer cells. Anticancer Drugs. 24:799–809. 2013. View Article : Google Scholar : PubMed/NCBI
45	Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H and Walker EA: Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. Br J Pharmacol. 171:636–645. 2014. View Article : Google Scholar : PubMed/NCBI
46	Ward SJ, Ramirez MD, Neelakantan H and Walker EA: Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. Anesth Analg. 113:947–950. 2011. View Article : Google Scholar : PubMed/NCBI
47	Bhalla K, Ibrado AM, Tourkina E, Tang C, Mahoney ME and Huang Y: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia. 7:563–568. 1993.PubMed/NCBI
48	Fan W: Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol. 57:1215–1221. 1999.PubMed/NCBI
49	Lieu CH, Chang YN and Lai YK: Dual cytotoxic mechanisms of submicromolar taxol on human leukemia HL-60 cells. Biochem Pharmacol. 53:1587–1596. 1997. View Article : Google Scholar : PubMed/NCBI
50	Torres K and Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res. 58:3620–3626. 1998.PubMed/NCBI
51	Onoda T, Ono T, Dhar DK, Yamanoi A and Nagasue N: Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 118:1309–1315. 2006. View Article : Google Scholar : PubMed/NCBI
52	Demidenko ZN, Kalurupalle S, Hanko C, Lim CU, Broude E and Blagosklonny MV: Mechanism of G1-like arrest by low concentrations of paclitaxel: Next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene. 27:4402–4410. 2008. View Article : Google Scholar : PubMed/NCBI
53	Mäkelä M, Sorsa T, Uitto VJ, Salo T, Teronen O and Larjava H: The effects of chemically modified tetracyclines (CMTs) on human keratinocyte proliferation and migration. Adv Dent Res. 12:131–135. 1998. View Article : Google Scholar : PubMed/NCBI
54	Myers SA and Wolowacz RG: Tetracycline-based MMP inhibitors can prevent fibroblast-mediated collagen gel contraction in vitro. Adv Dent Res. 12:86–93. 1998. View Article : Google Scholar : PubMed/NCBI
55	Ryan ME, Ramamurthy NS and Golub LM: Tetracyclines inhibit protein glycation in experimental diabetes. Adv Dent Res. 12:152–158. 1998. View Article : Google Scholar : PubMed/NCBI
56	Gu Y, Lee HM, Golub LM, Sorsa T, Konttinen YT and Simon SR: Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med. 37:450–460. 2005. View Article : Google Scholar : PubMed/NCBI
57	Sandler C, Ekokoski E, Lindstedt KA, Vainio PJ, Finel M, Sorsa T, Kovanen PT, Golub LM and Eklund KK: Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: Possible involvement of protein kinase C. Inflamm Res. 54:304–312. 2005. View Article : Google Scholar : PubMed/NCBI